Design and Synthesis of New Phthalazinone Derivatives Containing

Vol. 39, No. 2239 Biol. Pharm. Bull. 39, 239–251 (2016)

Regular Article

Design and Synthesis of New Phthalazinone Derivatives Containing Benzyl Moiety with Anticipated Antitumor Activity Magda Ismail Marzouk,*,a Soheir Ahmad Shaker,a Aisha Ali Abdel Hafiz,a and Khaled Zakaria El-Baghdadyb a

Department of Chemistry, Faculty of Science, Ain Shams University; Abassia, Cairo 11566, Egypt: and b Department of Microbiology, Faculty of Science, Ain Shams University; Abassia, Cairo 11566, Egypt. Received August 25, 2015; accepted November 9, 2015 The acetohydrazide derivative reacted with carbon electrophiles such as acid chlorides, acetylacetone, ethyl acetoacetate and aromatic aldehydes to give some interesting heterocyclic compounds. The hydrazide derivative reacted with acetophenone which in turn underwent Vielsmeier–Haack reaction. Also, the phthalazinethione has been synthesized and its behavior towards hydrazine hydrate, oxidizing agent and ethyl chloroacetate has been investigated. The newly synthesized compounds were characterized by spectroscopic data. The antimicrobial, the cytotoxic, and the antioxidant activities of some of the synthesized products were evaluated. Some of the tested compounds showed very strong cytotoxic activity with respect to the standard. Key words

phthalazinone; acetohydrazide; antitumor activity; antibacterial activity

Heterocyclic compounds containing hydrazine have received considerable attention because of their pharmacological properties and clinical applications.1–3) The diverse biological activities of various functional derivatives of 4-substituted alkyl-1-(2H)phthalazinones are well known. Some of the phthalazinone derivatives have found application in clinical medicine due to their pronounced antihypertensive properties,4) cardiotonic,5,6) anticonvulsant,7,8) antidiabetic,9,10) antithrombotic,11) antimicrobial,12,13) vasorelexant,14) antipyretic, analgesic, antitumor,15–18) and cytotoxic,19) while others have shown interesting vasodilator,20) vascular endothelial growth factor receptor (VEGFR) II inhibitory activities,21) and tuberculostatic activity allergic rhinitis.22) Phthalazin-1-(2H)ones bearing a substituent at 4-position represent key intermediates in the synthesis of various compounds with high interesting pharmacological properties such as the blood platelet aggregation inhibitor23) MV-5445 [1-(3-chloroanilino)4-phenylphthalazine] which has been found to be a selective phosphodiesterase V inhibitor24) or the thromboxane A2 synthetase inhibitor or bronchodilator, 2-[2-(1-imidazolyl)ethyl]-4-[3-pyridyl]phthalazine-1-(2H)one.25) During the last two decades there is a growing interest in the synthesis of several phthalazines as promising drug candidates for the treatment of cancer. The latter research efforts have led to the discovery of several leading phthalazines with different cellular and enzymatic targets. Inhibitors of poly(adenosine diphosphate-ribose)polymerases (PARPs) family of proteins are currently being evaluated as potential anticancer medicines at both preclinical and clinical levels.26) A series of 4-substituted-2H-phthalazin-1-ones have been investigated as potent orally bioavailable PARP inhibitor.27) For example, Olaparib (I), MRU-868 (II) and KU0058958 (III) are the most interesting PARP inhibitors based on the 4-substituted-2H-phthalazin-1-ones scaffold (Fig. 1). Interestingly, Prime et al.28) have reported a novel class of potent, selective, and orally bioavailable inhibitors of auroraA kinase based upon a 4-(pyrazole-3-ylamino)phenyl-2Hphthalazin-1-one scaffold. Compound (IV) inhibits aurora-A

with IC50 of 71 n M, also, it showed in vitro cytotoxic activity against HCT116 colon cell line with IC50 of 5.44 n M. Tubulin binding molecules29) have gained much interest among cytotoxic agents due to its success in clinical oncology. They differ from the other anticancer drugs in their mode of action because they target the mitiotic spindle and not the DNA, for example, E7010 (V). Oltipraz (VI) and related dithiolethione derivatives30) are an important class of chemopreventive agents that enhance the expression of carcinogen detoxication and antioxidant agents. Since, many synthetic compounds have been used to protect animals against a variety of cancer, hydrogen sulfide30) has been shown to be a potent endogenous gaseous mediator in many physiological and pathological processes. Hydrogen sulfide (H2S) in mammalian tissues is produced from L-cysteine, the sulfhydryl group (SH) be the essential species responsible for the biological activities of these compounds (Fig. 1). The observations outlined above, enthused us to develop new phthalazinone derivatives and to investigate their activities as antimicrobial, anticancer and antioxidant agents.

RESULTS AND DISCUSSION In the present investigation, we have reported the synthesis of some new phthalazinone derivatives. Some of the newly synthesized compounds were tested for their biological activity. A convenient four step procedure was used to synthesize the target 2-(4-benzyl-1-oxophthalazin-2(1H)-yl)acetohydrazide 4 as outlined in Chart 1. The commercially available phthalic anhydride was fused with phenylacetic acid in the presence of fused sodium acetate in an oil bath at 180°C to afford the 3-benzylidenephthalide 1, which was then reacted with hydrazine hydrate31) in boiling ethanol to give the benzylphthalazinone derivative 2. Oxidation of the phthalazinone derivative 2 with KMnO4 in the presence of K 2CO3 was failed to give 2,3-dihydrophthalazine-1,4-dione A, this result indicated that the phthalazinone derivative 2 exists in the tautomer form 2a not 2b (Chart 1).

To whom correspondence should be addressed. e-mail: [email protected] * © 2016 The Pharmaceutical Society of Japan

Biol. Pharm. Bull.

240

Fig. 1.

Chart 1.

Vol. 39, No. 2 (2016)

Structure of the Lead Anticancer Derivatives (I)–(VI) and the Designed Target Compounds 4, 12a, c, 15, 16 and 19

Synthesis of Compounds 1–5

Subsequent interaction of the benzylphthalazinone derivative 2a with ethyl chloroacetate in boiling acetone in the presence of anhydrous K 2CO3 led to the oxophthalazinyl acetate derivative 3. The structure of compound 3 was inferred from spectroscopic data. The IR showed the presence of 2C=O bands at 1735 and 1665 cm−1. The 1H-NMR spectrum showed

signals attributed to CH3, CH2, CH2Ph, CH2CO and aromatic protons at δ 1.22, 4.16, 4.33, 4.97, 7.09–8.48 ppm, respectively. The oxophthalazinyl acetate 3 was then reacted with hydrazine hydrate in boiling ethanol to give the desired acetohydrazide derivative 4. The structure of compound 4 was inferred from spectroscopic data. The IR showed the absence of the C=O

Biol. Pharm. Bull. Vol. 39, No. 2 (2016)241

Chart 2.


band attributed to the ester group and the appearance of bands at 3290 and 3318 cm−1 attributed to NH and NH2 groups. The 1 H-NMR spectrum devoid of any signals attributed to protons of ethyl group; instead it showed signals attributed to NH and NH2 protons at δ 4.56 and 9.31 ppm, respectively, as well as signals corresponding to CH2Ph, CH2CO and aromatic protons at δ 4.30, 4.75 and 7.29–8.27 ppm, respectively. A chemical prove for the structure of compound 3 was gained from its reaction with benzaldehyde in the presence of piperidine that yielded the adduct 5, which was devoid of signal corresponding to CH2CO protons in its 1H-NMR spectrum. Interaction of the acetohydrazide 4 with acetyl chloride and benzoyl chloride in the presence of dry benzene afforded the oxadiazol derivatives 6a and b (Chart 2). The structure of compounds 6a and b were confirmed from spectroscopic data. The reaction proceeded via nucleophilic attack followed by ring closure to afford the desired oxadiazol derivatives 6a and b. Treatment of the acetohydrazide 4 with acetyl acetone and ethyl acetoacetate afforded the pyrazol derivatives 7 and 8, respectively. The structures of compounds 7 and 8 were corroborated by spectroscopic data. The 1H-NMR spectrum of compound 7 showed the presence of 2CH3 groups at δ 2.02 ppm, in addition to a singlet signal at δ 5.63 ppm for the proton of the pyrazole ring. Also it showed signals at δ 4.33, 5.00 and 7.18–8.28 ppm for CH2Ph, CH2CO and aromatic protons respectively. The structure of compound 8 was supported from its IR spectrum which displayed a band at 1731 cm−1

corresponding to C=O group of the pyrazolone ring. The 1 H-NMR spectrum showed a singlet signal for CH3 protons at δ 1.55 ppm and a signal for CH2 protons group of the pyrazolone ring at δ 2.28 ppm, beside signals corresponding to CH2Ph, CH2CO and aromatic protons at δ 3.44, 4.29 and 7.26–8.70 ppm, respectively. The mass spectrum showed the molecular ion peak at m/z 374 which is in agreement with the molecular weight. Furthermore, 4′-fluoro acetophenone in methanol containing a catalytic amount of glacial acetic acid was reacted with compound 4 to give ethylidene acetohydrazide derivative 9. The structure of compound 9 was confirmed by spectroscopic data. The IR spectrum showed bands at 3214, 1714 (the high value is due to mutual induction), 1655 and 1614 cm−1 attributable to NH, 2C=O and C=N groups, respectively. The 1 H-NMR spectrum showed two singlet signals for CH3 and NH protons at δ 1.85 and 10.32 ppm, respectively, in addition to signals corresponding to CH2Ph, CH2CO and aromatic protons at δ 4.30, 4.87 and 7.16–8.27 ppm, respectively. Further confirmation for the structure of compound 9 was achieved through its reaction with Vilsmeier–Haack reagent (N,N-dimethyl formamide (DMF)/POCl3) that yielded the pyrazole carbaldehyde derivative 10. The 1H-NMR spectrum of compound 10 was in a good agreement with the suggested structure (cf. Experimental); it showed the disappearance of the signals corresponding to the methyl and the NH protons. The mass spectrum of compound 10 showed the molecular ion peak at m/z 466 which is coincident with the molecular weight

Biol. Pharm. Bull.

242

Chart 3.

Vilsmeier–Haack Reaction Mechanism

Chart 4.


(466) as supported the identity of the structure. A possible mechanism for the formylation of compound 9 is explained in Chart 3. Treatment of the acetohydrazide 4 with isatin in ethanol and drops of acetic acid yielded oxoindolinylidene acetohydrazide derivative 11. Its IR spectrum showed carbonyl absorption bands in addition to the NH absorption band 1719, 1646 and 3147 cm−1, respectively. Further evidence was gained from 1 H-NMR spectrum as it exhibited signals for 2NH at 11.25 and 12.67, beside signals corresponding to CH2Ph, CH2CO and aromatic protons at δ 4.34, 5.47 and 6.93–8.30 ppm, respectively. The mass spectrum showed the molecular ion peak

Vol. 39, No. 2 (2016)

at m/z 437 which is in agreement with the molecular weight. Interaction of the acetohydrazide 4 with the appropriate aldehydes namely benzaldehyde, 4-fluorobenzaldehyde, and 4-methoxybenzaldehyde in boiling ethanol yielded the corresponding Schiff bases 12a–c (Chart 4). The 1H-NMR spectra of compounds 12a–c were devoid of any signals for NH2 group and showed signals attributed to CH2Ph, NH, CH2CO, =CH and aromatic protons in the range of δ 4.30–4.92, 5.07–5.15, 5.31–5.53, 8.25–8.96 and 6.99–8.46 ppm, respectively. Also compound 12c showed a singlet signal at δ 3.80 ppm attributed to OCH3 protons. Further evidence were gained from mass spectra as they showed the correct molecular ion


Chart 5.

Reaction of Compound 4 with Methoxy Benzylidene

Chart 6.


peaks for compounds 12a and b and [M+−CH3, +3H] for compound 12c beside some important peaks. The reaction of compound 4 with 2-(4-methoxybenzylidene)malononitrile afforded the methoxy benzylidene derivative 12c not the pyrazolone derivative 12′c. The amino group in compound 4 underwent nucleophilic addition reaction to the double bond of 2-(4-methoxybenzylidene)malononitrile via Michael type addition reaction, by refluxing in ethanol containing few drops of piperidine to give a substance whose structure should be either the pyrazole derivative 12′c (route a) or the methoxy benzylidene derivative 12c (route b). The actual structure of the product was assigned as the methoxy benzylidene derivative 12c based on the spectroscopic data. The IR spectrum devoid any signal for C≡N group. The proton 1H-NMR spectrum showed signals attributed to NH and=CH protons, and was devoid of NH2 signal which should have appeared if the reaction product was 12′c (Chart 5). The Schiff bases 12a and b were allowed to react with thioglycolic acid in boiling benzene to yield thiazolidinyl acetamide derivatives 13a and b, respectively (Chart 4). The reaction takes place via thia addition type on azamethine moiety followed by 5-exo-trig ring closure. The structures of compounds 13a and b were corroborated by spectroscopic data. The 1H-NMR spectrum showed signals attributed to CH2Ph, CH2CO, SCH2, aromatic and NH protons in the range of δ 3.88–4.19, 4.26–4.32, 4.78–4.96, 5.33–5.80, 7.16–8.29, 10.59–11.71 ppm, respectively. The mass spectra of compounds 13a and b showed the correct molecular ion peaks at m/z 470 and 488, respectively.

The reaction of thiol to form a carbon–sulfur bond constitutes a key reaction in biosynthesis as well as in the synthesis of biologically active compounds.32) The schiff base 12b was submitted to react with thiophenol in benzene with stirring to yield the thia type adduct 14. The structure of compound 14 was corroborated by spectroscopic data. The IR spectrum showed bands at 3298, 1734, 1653 cm−1 attributed to NH and 2C=O, the high value of νC=O is due to mutual induction. The 1H-NMR spectrum showed signals attributed to NH, [CH2Ph, CH2CO], SCH, aromatic protons, at δ 1.85 4.24–4.31, 5.01, 7.21–8.44 ppm, respectively. Reaction of acetohydrazide 4 with benzenesulfonyl chloride in pyridine yielded compound 15. The structure of the synthesized compound 15 was elucidated by studying its IR, 1 H-NMR, mass spectra, and elemental analysis. The IR spectrum showed bands at 1343 and 1170 cm−1 attributed to SO2 group beside bands for NH and C=O at 3220, 1703, 1635 cm−1. The 1H-NMR spectrum showed signals attributed to CH2Ph, CH2CO, aromatic and NH protons at δ 4.27, 4.71, 7.19–8.26, 9.74, 9.98 ppm, respectively. The mass spectrum showed the molecular ion peak at m/z 448 which is in agreement with the molecular weight. Treatment of the phthalazinone derivative 2a with phosphorus pentasulfide in boiling dry toluene yielded the phthalazinethione derivative 16. The 1H-NMR spectrum showed signals attributed to CH2Ph, aromatic and NH protons at δ 4.37, 7.24–8.91, 11.80 ppm, respectively. The IR spectrum showed bands at 3159 and 1242 cm−1 attributed to NH, C=S and devoid any band of C=O. The mass spectrum showed the

Biol. Pharm. Bull.

244

molecular ion peak at m/z 252 which is in agreement with the molecular weight. The reaction of compound 16 with hydrazine hydrate in boiling ethanol yielded the hydrazine derivative 17 (Chart 6). The IR spectrum revealed NH2 and NH stretching bands at 3379 cm−1. While the 1H-NMR spectrum revealed the presence of the NH2 and NH protons as a broad singlet at 4.78 ppm, in addition to the other aromatic protons appearing as multiplet at 7.27–8.42 ppm and to CH2Ph at 4.30 ppm. Oxidation33) of the phthalazinethione 16 with concentrated HNO3 at room temperature afforded the sulfonic acid derivative 18. The structure of compound 18 was inferred from its solubility in sodium bicarbonate solution and spectroscopic data. The 1H-NMR spectrum revealed the presence of the OH proton as a singlet signal at 13.25 ppm beside CH2Ph and aromatic protons at δ 3.35 and 7.90–9.00 ppm, respectively. On the other hand, oxidation of the phthalazinethione 16 with chlorine gas in acetic acid gave the sulfonyl chloride derivative 19. The analytical and the spectral data are in a good agreement with the proposed structure. The 1H-NMR spectrum revealed the presence of signals at δ 4.29 and 7.18–8.26 ppm attributed to CH2Ph and aromatic protons. The mass spectrum of compound 19 showed the correct molecular ion peaks at m/z 318. Alkylation of the phthalazinethione 16 with ethyl chloroacetate in the presence of anhydrous K 2CO3 in boiling acetone yielded the ethyl acetate derivative 20. The reaction takes place via SN2 mechanism in which the lone pair of the sulfur atom attacks the chloro moiety ester, while the function of K 2CO3 is to pull off the chloride ion. Here the authors offer a speculation to explain the activities of the thioamide and iminothiol equilibrium based on their thermodynamic and kinetic controlled formation under the experimental conditions. Firstly, in the presence of anhydrous K 2CO3 and acetone, the conjugate base of iminothiol tautomer is more thermodynamically stable than the conjugate base derived from thioamide tautomer via the back donation involving the vacant D -orbital of the sulfur atom. Therefore, the iminothiol tautomer is more predominant under such conditions. Secondly, the sulfur anion is a stronger nucleophile than the nitrogen anion (nucleophilicity is kinetic control). Thus, the iminothiol tautomer is more thermodynamically and kinetically formed than thioamide tautomer, which spells out the reactivity of the iminothiol tautomer (Fig. 2). The structure of compound 20 was confirmed from spectroscopic data. The IR showed band at 1737 cm−1 attributed to C=O of the ester group. The 1H-NMR spectrum revealed the presence of signals at δ 1.19, 4.12–4.17, 4.30, 4.69, 7.15–8.28 ppm attributed to CH3, CH2, CH2Ph, CH2S and aromatic protons, respectively. Pharmacology Antibacterial Activity Staphylococcus aureus was significantly inhibited by com-

Fig. 2.

Thioamide–Iminothiol Tautomerism

Vol. 39, No. 2 (2016)

pounds 12c, 17–19 (Fig. 3 and Table 1). For other compounds no activity on Staphylococcus aureus was detected. For Gram-negative clinical isolates only compound 7 significantly inhibited both Escherichia coli and Pseudomonas aeruginosa, while compounds 12c and 19 inhibited only Escherichia coli. Both isolates were resistant to erythromycin. The mode of action of compounds 17 and 18 was different from compounds 7, 12c and 19, since they inhibited the growth of Gram-positive clinical isolate, while, compound 7 inhibited the growth of Gram-negative clinical isolates growth. Compounds 12c and 19 were able to inhibit both isolates. Sulfones are competitive inhibitors of folic acid synthesis and are used as bacteriostatic and in the treatment of Leprosy.34) Many of aryl sulfones are used as antifungal, antibac-

Fig. 3. Diameter of Inhibition Zones for Effective Compounds on A) Staphylococcus aureus, B) Escherichia coli and C) Pseudomonas aeruginosa V: vancomycin; E: erythromycin and T: tetracyclin.

Table 1.

The Antibacterial Activities of Some Compounds Diameter of inhibition zones (cm)

Compd. no.

Staphylococcus aureus

Escherichia coli

Pseudomonas aeruginosa

DMSO 3 4 6a 6b 7 12a 12b 12c 13a 16 17 18 19 20 Vancomycin Erythromycin Tetracycline

0 0 0 0 0 0 0 0 2.4±0.01 0 0 1.7±0.05 2.4±0.1 3.0 0 2±0.05 3±0.1 1.8±0.05

0 0 0 0 0 1.7±0.05 0 0 0.37±0.01 0 0 0 0 3.12 0 0 0 1.1±0.05

0 0 0 0 0 1.9±0.05 0 0 0 0 0 0 0 0 0 0 0 0


Fig. 4.

Table 2.

Cytotoxic Activity of the Tested Compounds on Different Cell Lines

Cytotoxicity (IC50) of the Tested Compounds on Different Cell Lines

Compd. no. 4 12a 12c 15 16 19 20 5-FU

IC50 (µg/mL)a) HePG2

HCT-116

PC3

MCF-7

29.9±1.33 85.9±5.71 53.8±4.32 7.8±0.23 5.6±0.22 93.7±5.97 95.1±6.42 7.9±0.12

12.9±0.96 96.5±6.65 62.9±2.97 8.5±0.31 7.7±0.25 93.6±6.28 >100 5.3±0.14

26.9±1.57 95.4±5.30 66.6±4.36 8.9±0.51 8.6±0.34 >100 >100 8.3±0.25

19.2±1.64 94.9±5.18 41.2±2.96 8.9±0.62 5.0±0.41 >100 >100 5.4±0.21

a) IC50 (µg/mL): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak), above 100 (non-cytotoxic).

terial or antitumor agents35) and inhibitors for several36) cyclic oxygenase-2 (COX-2). Compounds containing C=N may act as a Michael acceptor for nucleophiles containing NH2 or sulfhydryl SH groups. In case of enzymes they are converted from the active form to the inactive form by these compounds. Some of these enzymes are responsible for building cell walls of bacteria and /or fungi; which explain the activities of compounds 7, 12c, 17–19. Antitumor Activity Using in Vitro Ehrlich Ascites Assay We assessed the cytotoxic action of the compounds listed in Table 2 against four human tumor cell lines namely; hepatocellular carcinoma (liver) HePG2, colon cancer HCT-116, human prostate cancer cell line PC3, and mammary gland breast MCF-7. In general, activity was observed by all of these molecules ranged from very strong to non-cytotoxic. The optimal results were observed for compounds 15 and 16 (very strong activity) with IC50 7.8±0.23, 5.6±0.22 µg/ mL for HePG-2 cell, 8.5±0.31, 7.7±0.25 µg/mL for HCT-116 cell, 8.9±0.51, 8.6±0.34 µg/mL for PC3 cell and 8.9±0.62, 5.0±0.41 µg/mL for MCF-7 cell, respectively. Compound 16 exhibited stronger activity (IC50 5.6±0.22, 0±0.41 µg/mL) than the 5-fluorouracil (5-FU) as a standard (7.9±0.12, 5.4±0.21 µg/ mL) for HePG2 and MCF-7, respectively. Also it showed approximately equal activity to the 5-FU as a standard for PC3 cell line with IC50 8.6±0.34 and 8.3±0.25 µg/mL, respectively. Compound 15 showed approximately equal activity to the ascorbic acid as a standard for HePG2 and PC3 cells with IC50 7.8±0.23, 8.9±0.51 and 7.9±0.12, 8.3±0.25 µg/mL, respectively. Compound 4 showed strong activity towards HCT-116 cell

(12.9±0.69 µg/mL), and MCF-7 cell (19.2±1.64 µg/mL), also it showed moderate activity towards HePG-2 cell (29.9±1.33 µg/ mL) and PC3 cell (26.9±1.57 µg/mL). While compounds 12a, c, 19 and 20 observed activity ranged from moderate to noncytotoxic with IC50 41.2±2.96 to >100. [The relative viability of cells (%) for the tested compounds is depicted in Tables S1 and S2 (Supplementary materials)]. Antioxidant Activity Using 2.2′-Azino-bis(3-ethylbenzthiazoline-6-sulfonic (ABTS) Acid Inhibition Seven compounds were tested for antioxidant activity as reflected in the ability to inhibit oxidation in rat brain and kidney homogenates Table 3. Compounds 16 and 15 showed high % inhibition 85.3, 78.4%, respectively. While the rest of the compounds 4, 12a, c, 19 and 20 exhibited moderate to weak antioxidant activity ranged from 53.9–30.1%. Bleomycin-Dependent DNA Damage The bleomycin is a family of glycopeptides antibiotics that are used routinely as antitumor agents. The bleomycin assay has been adopted for assessing the pro-oxidant effect of food antioxidants. The antitumor antibiotic bleomycin binds iron ions and DNA. The bleomycin–iron complex degrades DNA when heated with thiobarbituric acid (TBA) to yield a pink chromogenic. Upon the addition of suitable reducing agents antioxidant competes with DNA and diminishes chromogenic formation.37) To show the mechanism of action of the tested compounds 4, 12a, c, 15, 16, 19 and 20, their protective activity against DNA damage induced by the bleomycin–iron complex were examined. The results in Table 3 showed that compounds 4, 12a, c, 15, 16, 19 and 20 have the ability to protect DNA from

Biol. Pharm. Bull.

246

Table 3. Antioxidant Activity and Bleomycin Dependent DNA Damage for the Tested Compounds Compd. no. 4 12a 12c 15 16 19 20 Ascorbic acid

Antioxidant activity (ABTS method) Bleomycin dependent DNA damage Absorbance Inhibition (%) 0.222 0.337 0.268 0.104 0.071 0.300 0.302 0.053

53.9 30.1 44.4 78.4 85.3 37.7 37.3 89.0

0.096 0.137 0.088 0.072 0.096 0.130 0.142 0.073

All experiments were performed three times. The data are expressed as the mean±standard error of the mean (S.E.M.).

the induced damage by bleomycin. Compound 15 showed very high protection (0.072) against DNA damage induced by the bleomycin–iron complex which is approximately equal to ascorbic acid as a standard (0.073). Compounds 4, 12c and 16 showed high ability. On the other hand, the rest of the compounds 12a, 19 and 20 exhibited moderate activities. Thus, all the tested compounds diminish the chromogenic formation between the damage DNA and TBA. Structure–Activity Relationship (SAR) DNA is made of chemical building blocks called nucleotides. The four types of nitrogen bases found in nucleotides are: adenine (A), thymine (T), guanine (G) and cytosine (C). The base adenine always pairs with thymine, while guanine always pairs with cytosine through hydrogen bond. The cytotoxic activity towards different cell lines depends on two factors: (i) The formation of intermolecular hydrogen bond with DNA bases (ii) the positive charge on the tested compounds attracted to the negative charge on the cell wall. By comparing the experimental cytotoxicity of the compounds reported in this study to their structures, the following SAR were postulated. ・ Compound 16 showed very strong activity, this is due to the presence of the sulfhydryl group (SH) and NH groups which may be added to any unsaturated moiety in DNA (thia or aza Michael addition) or forming hydrogen bond with either one of the nucleobases of the DNA and causes it damage. ・ Compound 15 showed very strong activity, this is due to the presence of 2NH groups available to form hydrogen bond with either one of the nucleobases of the DNA and causes it damage. Also the presence of the SO2Ph group as a strong electron attracting group rendered the molecule positively charged forming electrostatic attraction with the DNA nucleobases. Moreover, the SO2 group acts on the mitotic spindle.29) ・ Compound 4 contains NH and NH2 groups forming hydrogen bond with either one of the nucleobases of the DNA and causes it damage. ・ Incorporation of –N=CHAr moiety has rendered compounds 12a and c with moderate to weak cytotoxicity activities against the four tumor cell types. ・ Compounds 12a and c contain only 1NH groups forming hydrogen bond with either one of the nucleobases of the DNA and causes it damage but to a little effect. ・ Conversion of compound 16 to compounds 19 and 20 re-

Vol. 39, No. 2 (2016)

duces the cytotoxic activity against all cell line may be due to the lack of the sulfhydryl group.

CONCLUSION The objective of the present study was to synthesize the phthalazinone based compounds scafold and study their antibacterial, cytotoxicity, antioxidant and bleomycin dependent DNA damage activities. Staphylococcus aureus was significantly inhibited by compounds 12c, 17–19. For other compounds no activity on Staphylococcus aureus was detected. For Gram-negative clinical isolates only compound 7 significantly inhibited both Escherichia coli and Pseudomonas aeruginosa, while compounds 12c and 19 inhibited only Escherichia coli. Both isolates were resistant to erythromycin. The tested compounds showed very strong to non-cytotoxic activity against four anticancer cell lines. The best results were observed for compounds 15 and 16 (very strong activity). Compound 15 showed approximately equal activity to the 5-FU as a standard against HePG2 and PC3 cells. Compound 16 exhibited stronger activity than the 5-FU as a standard against HePG2 and MCF-7.

EXPERIMENTAL Chemistry All melting points were uncorrected. IR spectra were recorded in KBr on FTIR Mattson Spectrometers. 1 H-NMR spectra were measured on Varian Gemini 300 MHz instrument with chemical shift (δ) expressed in ppm downfield from TMS. MS were recorded on Shimadzu GC-MS-QP 1000 Ex and MS_5988 instruments at 70 eV. All the spectral measurements as well as elemental analyses were carried out at the Micro analytical Center of Cairo University, Egypt and at Faculty of Pharmacy, Ain Shams University. Compound 2 was prepared according to the literature procedure.31) All products were characterized by IR; 1H-NMR; mass spectroscopy and elemental analyses. Synthesis of Ethyl 2-(4-Benzyl-1-oxophthalazin-2(1H)yl)acetate (3) A solution of 2 (2.36 g, 0.01 mol), ethyl chloroacetate (4.4 g, 0.04 mol) and anhydrous potassium carbonate (5.5 g, 0.04 mol) in acetone (60 mL) was heated on a water bath for 20 h. The excess solvent was evaporated and the reaction mixture was poured on water. The separated solid was filtered off and recrystallized from petroleum ether 60–80°C to give compound 3. Violet crystals; yield (2.1 g, 66%); mp 128–130°C (Lit.,36) mp 76–78°C); 1H-NMR (CHCl3) δ: 1.22 (3H, t, J=6.0 Hz), 4.16 (2H, q, J=6.0 Hz), 4.33 (2H, s), 4.97 (2H, s), 7.09–8.48 (9H, m). IR (KBr) cm−1: 1735, 1665. MS m/z: 322 (M+), 249, 91. Anal. Calcd for C19H18N2O3: C, 70.79; H, 5.63; N, 8.69. Found: C, 70.80; H, 5.58; N, 8.64. Synthesis of 2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)acetohydrazide (4) A mixture of 3 (3.22 g, 0.01 mol) and hydrazine hydrate (0.05 mL, 0.01 mol) in ethanol (30 mL) was refluxed for 3 h. The separated solid was filtered off and recrystallized from ethanol to give compound 4. White crystals; yield (2.6 g, 85%); mp 184–186°C (Lit.,31) mp 130–132°C); 1 H-NMR (DMSO-d6) δ: 4.30 (2H, s), 4.56 (2H, s), 4.75 (2H, s), 7.26–8.27 (9H, m), 9.31 (1H, s). IR (KBr) cm−1: 3290, 3318, 1661, 1615. MS m/z: 308 (M+), 277, 91.05. Anal. Calcd for C17H16N4O2: C, 66.22; H, 5.23; N, 18.17. Found: C, 66.36; H, 5.27; N, 18.20.


Synthesis of Ethyl 2-(4-Benzyl-1-oxophthalazin-2(1H)yl)-3-phenylacrylate (5) A mixture of 3 (3.22 g, 0.01 mol), benzaldehyde (1 mL, 0.01 mol) and piperidine (1 mL) in ethanol (30 mL) was refluxed for 3 h. The reaction mixture was cooled and the separated solid was filtered off and recrystallized from petroleum ether to give compound 5. White crystals; yield (2.6 g, 64%); mp 174–176°C; 1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J=6.0 Hz), 4.15–4.23 (2H, q, J=6.0 Hz), 4.91 (2H, s), 7.09–8.43 (15H, m). IR (KBr) cm−1: 3100, 1735, 1656. MS m/z: 396 (M+−CH3, +H·), 294, 250, 249, 207, 176, 178, 130. Anal. Calcd for C26H22N2O3: C, 76.08; H, 5.40; N, 6.82. Found: C, 76.11; H, 5.43; N, 6.86. General Procedure for the Synthesis of 6a, b A solution of 4 (3.08 g, 0.01 mol), acetyl chloride or benzoyl chloride (0.01 mol) in benzene (30 mL) was refluxed for 4 h. The separated solid was filtered off dried and recrystallized from the suitable solvent to give compounds 6a and b. 4 -Benz yl-2-((5-methyl-1,3,4 -oxadiazol-2-yl)methyl)phthalazin-1(2H)-one (6a) Brown crystals; yield (2.87 g, 82%); mp 222–224°C; ethanol; 1H-NMR (DMSO-d6) δ: 2.49 (3H, s), 4.31 (2H, s), 5.50 (2H, s), 7.16–8.30 (9H, m). IR (KBr) cm−1: 3136, 2946, 1634. MS m/z: 318 (M+−CH3, +H), 290, 250, 249, 222, 130. Anal. Calcd for C19H16N4O2: C, 68.66; H, 4.85; N, 16.86. Found: C, 68.17; H, 5.10; N, 16.80. 4 -Ben z yl-2-((5-phenyl-1,3,4 -oxadiazol-2-yl)methyl)phthalazin-1(2H)-one (6b) White crystals; yield (3.2 g, 80%); mp 228–230°C; toluene; 1 H-NMR (DMSO-d6) δ: 4.33 (2H, s), 4.96 (1H, s), 7.19–8.30 (14H, m). IR (KBr) cm−1: 3192, 1650, 1604. MS m/z: 394 (M+), 383, 381, 120, 92. Anal. Calcd for C24H18N4O3: C, 73.08; H, 4.60; N, 14.20. Found: C; 73.20, H; 4.53, N; 14.25. Synthesis of 4-Benzyl-2-(2-(3,5-dimethyl-1H-pyrazol1-yl)-2-oxoethyl)phthalazin-1(2H)-one (7) A solution of 4 (3.08 g, 0.01 mol) and acetyl acetone (1 mL, 0.01 mol) in ethanol (30 mL) was refluxed for 3 h. The separated solid was filtered off and recrystallized from toluene to give compound 7. Orange crystals; yield (2.73 g, 70%); mp 206–208°C; 1H-NMR (DMSO-d6) δ: 2.02 (6H, s), 4.33 (2H, s), 5.00 (2H, s), 5.63 (1H, s), 7.18–8.28 (9H, m). IR (KBr) cm−1: 3026, 1684, 1652. MS m/z: 372 (M+−H2O), 277, 250, 249, 237, 222, 195, 193, 130, 107, 102, 91. Anal. Calcd for C22H20N4O2: C, 70.95; H, 5.41; N, 15.04: Found: C, 71.00; H, 5.69; N, 15.14. Synthesis of 4-Benzyl-2-(2-(3-methyl-5-oxo-4,5-dihydropyrazol-1-yl)-2-oxoethyl)phthalazin-1(2H)-one (8) A solution of compound 4 (3.08 g, 0.01 mol) and ethyl acetoacetate (1.3 mL, 0.01 mol) in ethanol (30 mL) was refluxed for 3 h. The separated solid was filtered off and recrystallized from ethanol to give compound 8. White crystals; yield (2.94 g, 70%); mp 138–136°C; 1H-NMR (CDCl3) δ: 1.55 (3H, s), 2.28 (2H, s,), 3.44 (2H, s), 4.29 (2H, s), 7.26–8.70 (9H, m,). IR (KBr) cm−1: 1731, 1689, 1654. MS m/z: 374 (M+), 368, 286, 188, 186, 185, 131, 117, 71, 58, 57, 56. Anal. Calcd for C21 H18 N4 O3: C, 67.37; H, 4.85; N, 14.96. Found: C, 67.45; H, 4.93; N, 14.87. Synthesis of 2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)-N′(1-(4-fluorophenyl)ethylidene)acetohydrazide (9) A mixture of compound 4 (3.08 g, 0.01 mol) and 4′-fluoro acetophenone (1.38 g, 0.01 mol) in glacial acetic acid (20 mL) was refluxed for 5 h, cooled to room temperature, and then poured over crushed ice and allowed to stand overnight. The separated solid was collected by filtration, dried and recrystallized

from ethanol to give 9. Brown crystals; yield (3.4 g, 80%); mp 220–222°C; 1H-NMR (DMSO-d6) δ: 1.85 (3H, s), 4.30 (2H, s), 4.87 (2H, s), 7.16–8.27 (13H, m), 10.32 (1H, s). IR (KBr) cm−1: 3214, 1714, 1655, 1614. MS m/z: 428 (M+, 0.00), 249, 91. Anal. Calcd for C25H21FN4O2: C, 70.08; H, 4.94; N, 13.08. Found: C, 70.36; H, 4.96; N, 13.12. Synthesis of 1-(2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)acetyl)-3-(4-f luorophenyl)-1H-pyrazole-4-carbaldehyde (10) POCl3 (0.612 g, 0.004 mol) was added to cold DMF (0.117 g, 0.0016 mol) at 0°C, and a solution of compound 9 (0.25 g, 0.0006 mol) in DMF (10 mL) was added dropwise, then the reaction mixture was heated on water bath at 65–70°C for 4 h; the reaction mixture was cooled and then poured into cold water; the separated solid was filtered off, washed with water, dried and recrystallized from benzene/petroleum ether 60–80°C (2 : 1) to give 10. White crystals; yield (1.8 g, 40%); mp 110–113°C; 1H-NMR (DMSO-d6) δ: 3.69 (2H, s), 5.06 (2H, s), 7.18 (1H, s), 7.20–8.26 (13H, m), 8.28 (1H, s). IR (KBr) cm−1: 1738, 1637. MS m/z: 466 (M+), 237, 128. Anal. Calcd for C27H19FN4O3: C, 69.52; H, 4.11; N, 12.01. Found: C, 69.43; H, 4.33; N, 12.24. Synthesis of 2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)-N′(2-oxoindolin-3-ylidene)acetohydrazide (11) The acetohydrazide derivative 4 (3.08 g, 0.01 mol) was condensed with isatin (1.47 g, 0.01 mol) in ethyl alcohol (25 mL) in the presence of few drops of acetic acid on a water bath for 3 h. The solvent was evaporated and the reaction mixture was poured into crushed ice. The separated solid was filtered off, dried and recrystallized from ethanol to give 11. Brown crystals; yield (4.0 g, 92%); mp 254°C (dec); 1H-NMR (DMSO-d6) δ: 4.34 (2H, s), 5.47 (2H, s), 6.93–8.30 (13H, m), 11.25 (1H, s), 12.67 (1H, s). IR (KBr) cm−1: 3147, 1719, 1696, 1654, 1623. MS m/z: 437 (M+), 277, 91. Anal. Calcd for C25H19N5O3: C, 68.64; H, 4.38; N, 16.01. Found: C, 68.83; H, 4.26; N, 16.10. General Procedure for the Synthesis of 12a–c Method (A) A mixture of compound 4 (3.08 g, 0.01 mol) and aromatic aldehydes namely benzaldehyde, 4-fluoro benzaldehyde, and 4-methoxy benzaldehyde (2 mL) in boiling ethanol (30 mL) was refluxed for 3 h. The separated solid was filtered off and recrystallized from the suitable solvent to give compounds 12a–c. 2-(4-Benzyl-1-oxophthalazin-2(1H )-yl)-N′-benzylideneacetohydrazide (12a) White crystals; yield (2.76 g, 71%); mp 202–204°C; ethanol; 1 H-NMR (CDCl3) δ: 4.32 (2H, s), 5.07 (1H, s), 5.53 (2H, s), 7.26–8.46 (14H, m), 8.96 (1H, s). IR (KBr) cm−1: 3192, 1688, 1646. MS m/z: 396 (M+), 278, 250, 249, 222, 90, 77. Anal. Calcd for C24H20 N4O2: C, 72.71; H, 5.08; N, 14.13. Found: C, 72.64; H, 5.12; N, 14.20. N′-(4-Fluorobenzylidene)-2-(4-benzyl-1-oxophthalazin-2(1H)yl)acetohydrazide (12b) White crystals; yield (3.1 g, 75%); mp 208–210°C; ethanol; 1 H-NMR (CDCl3) δ: 4.30 (2H, s), 5.15 (1H, s), 5.50 (2H, s), 7.30–8.33 (13H, m), 8.25 (1H, s). IR (KBr, cm−1): 3196, 1686, 1645. MS m/z: 414 (M+), 278, 277, 250, 249, 222, 108, 91. Anal. Calcd for C24H19FN4O2: C, 69.55; H, 4.62; N, 13.52. Found: C, 69.74; H, 4.60; N, 13.58. N′-(4-Methoxybenzylidene)-2-(4-benzyl-1-oxophthalazin-2(1H)yl)acetohydrazide (12c) White crystals; yield (2.8 g, 68%); mp 198–200°C; ethanol;

248 1

Biol. Pharm. Bull.

H-NMR (DMSO-d6) δ: 3.80 (3H, s), 4.32 (2H, s), 4.91 (1H, s), 5.30 (2H, s), 6.97–8.27 (13H, m), 8.30 (1H, s). IR (KBr) cm−1: 3149, 3141, 1698, 1633. MS m/z (%): 414 (M+−CH3, +3H), 250, 249, 91, 89, 77, 59. Anal. Calcd for C25H22N4O3: C, 70.41; H, 5.20; N, 13.14. Found: C, 70.48; H, 5.14; N, 13.17. Method (B) The acetohydrazide derivative 4 (3.08 g, 0.01 mol) was refluxed with 2-(4-methoxybenzylidene)malononitrile (1.84 g, 0.01 mol) in ethyl alcohol (30 mL) in the presence of few drops of piperidine for 6 h. The separated solid after cooling was filtered off, dried and recrystallized from the ethanol to give compound 12c. General Procedure for the Synthesis of 13a and b A solution of compounds 12a and b (0.01 mol) and thioglycolic acid (0.7 mL, 0.01 mol) in dry benzene (30 mL) was refluxed for 6 h. The separated solid was filtered off and recrystallized from the suitable solvent to give compounds 13a and b. 2- (4 -Ben z yl-1- oxophthalazi n-2(1H ) -yl) -N- (4 - oxo -2phenylthiazolidin-3-yl)acetamide (13a) White crystals; yield (3.0 g, 64%); mp 184–186°C; ethanol; 1 H-NMR (DMSO-d6) δ: 3.88 (2H, s), 4.26 (2H, s), 4.78 (2H, s), 5.80 (1H, s), 7.18–8.27 (14H, m), 10.59 (1H, s). IR (KBr, cm−1): 3203, 1730, 1697, 1631. MS m/z: 470 (M+), 277, 250, 249, 222, 178, 91, 77. Anal. Calcd for C26H22N4O3S: C, 66.37; H, 4.71; N, 11.91; S, 6.81. Found: C, 66.69; H, 4.64; N, 11.97; S, 6.89. 2 - (4 - B e n z y l -1- oxo p h t h a l a z i n -2 (1 H ) -y l ) - N - (2 - (4 fluorophenyl)-4-oxothiazolidin-3-yl)acetamide (13b) White crystals; yield (3.5 g, 73%); mp 178–180°C; ethanol; 1 H-NMR (DMSO-d6) δ: 4.19 (2H, s), 4.32 (2H, s), 4.96 (2H, s), 5.33 (1H, s), 7.16–8.29 (13H, m), 11.71 (1H, s). IR (KB, cm−1): 3206, 1729, 1699. MS m/z: 488 (M+), 489 (M+1), 250, 249, 165, 91. Anal. Calcd for C26H21FN4O3S: C, 63.92; H, 4.33; N, 11.47; S, 6.56. Found: C, 64.23; H, 4.27; N, 11.45; S, 6.58. Synthesis of 2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)-N′((4-fluorophenyl)(phenylthio)methyl)acetohydrazide (14) A solution of compound 12b (4.14 g, 0.01 mol) and thiophenol (1.1 mL, 0.01 mol) in dry benzene (30 mL) was refluxed for 3 h with stirring. The separated solid was filtered off and recrystallized from petroleum ether 60–80°C to give compound 14. Yellowish white crystals; yield (3.7 g, 73%); mp 118–120°C; 1 H-NMR (CDCl3) δ: 1.85 (2H, br s), 4.24–4.31 (4H, s), 5.01 (1H, s), 7.21–8.44 (18H, m). IR (KBr) cm−1: 3298, 1734, 1653. MS m/z: 522 (M+−2), 278, 277, 249, 110, 92, 58. Anal. Calcd for C30H25FN4O2S: C, 68.68; H, 4.80; N, 10.68; S, 6.11. Found: C, 68.73; H, 4.76; N, 10.57; S 6.14. Synthesis of 2-(4-Benzyl-1-oxophthalazin-2(1H)-yl)-N′(phenylsulfonyl)acetohydrazide (15) Benzenesulfonyl chloride (0.176 g, 0.001 mol) was added to the solution of acetohydrazide derivative 4 (0.308 g, 0.001 mol) in pyridine (10 mL) at 0°C. The resulting mixture was stirred at room temperature for 5 h. At the end of this period, the reaction mixture was poured into ice water. The precipitate was filtered off, dried, and crystallized from ethanol to give compound 15. Off white crystals; yield (3.3 g, 75%); mp 234–236°C; 1H-NMR (300 MHz, DMSO-d6) δ: 4.27 (2H, s), 4.71 (2H, s), 7.19–8.26 (14H, m), 9.74 (1H, s), 9.98 (1H, s). IR (KBr) cm−1: 3220, 1703, 1635, 1343, 1170. MS m/z: 448 (M+), 277, 91. Anal. Calcd for C23H20N4O4S: C, 61.59; H, 4.49; N, 12.49; S, 7.15. Found: C, 61.46; H, 4.46; N, 12.50; S, 7.12. 4-Benzylphthalazine-1(2H)-thione (16) A solution of compound 2 (2.36 g, 0.01 mol) and P2S5 (8 g, 0.02 mol) in dry

Vol. 39, No. 2 (2016)

toluene (50 mL) was refluxed for 2 h. The reaction mixture was filtered off while hot and concentrated. The separated solid on cooling was filtered off and recrystallized from toluene to give compound 16. Yellow crystals; yield (1.25 g, 50%); mp 160–162°C; 1H-NMR (CDCl3) δ: 4.37 (2H, s), 7.24–8.91 (9H, m), 11.80 (1H, s). IR (KBr) cm−1: 3159, 1242. MS m/z (%): 252 (M+), 251, 91, 69. Anal. Calcd for C15H12N2S: C, 71.40; H, 4.79; N, 11.10; S, 12.71. Found: C, 71.47; H, 4.71; N, 11.04; S, 12.80. Synthesis of 1-(4-Benzylphthalazin-1-yl)hydrazine (17) A solution of compound 16 (2.5 g, 0.01 mol) and hydrazine hydrate (0.5 mL, 0.01 mol) in ethanol (30 mL) was refluxed for 3 h. The separated solid was filtered off and crystallized from benzene to give compound 17. Orange crystals; yield (1.6 g, 65%); mp 228–230°C; 1H-NMR (DMSO-d6) δ: 4.30 (2H, s), 4.78 (3H, s), 7.27–8.42 (9H, m). IR (KBr) cm−1: 3379, 1616. MS m/z: 234 (M+−NH2), 129, 102, 92, 91, 76. Anal. Calcd for C15H14N4: C, 71.98; H, 5.64; N, 22.38. Found: C, 72.11; H, 5.60; N, 22.22. Synthesis of 4-Benzylphthalazine-1-sulfonic Acid (18) Nitric acid (0.01 mol, 60–68%) was added to compound 16 (2.52 g, 0.01 mol) with stirring for 3 d, then poured on water, the separated solid was filtered off, washed with water and recrystallized from benzene to give compound 18. Yellow crystals; yield (1.5 g, 50%); mp 208–210°C; 1H-NMR (DMSO-d6) δ: 3.35 (2H, s), 7.90–9.00 (9H, m), 13.25 (1H, br s). IR (KBr) cm−1: 3431, 3170, 1602, 1200, 1050, 650. MS m/z (%): 270 (M+−O2, +2H·), 220, 178, 176, 165, 150, 149, 130, 104, 92, 77. Anal. Calcd for C15H12N2O3S: C, 59.99; H, 4.03; N, 9.33; S, 10.68. Found: C, 60.20; H, 3.97; N, 9.41; S, 10.61. Synthesis of 4-Benzylphthalazine-1-sulfonyl Chloride (19) Molecular chlorine was bubbled through a solution of compound 16 (2.52 g, 0.01 mol) in glacial acetic acid (25 mL) and water (3 mL) at 30°C for 20 min, upon completion of the chlorination, water (30 mL) was added and the solution was washed with chloroform (50 mL aliquots), the combined chloroform layers were washed with 2.5% sodium hydroxide (2×50 mL aliquots), the chloroform was then dried over MgSO4, filtered off, and left for slow evaporation. The separated solid was filtered off and recrystallized from petroleum ether 40–60°C to give compound 19. Yellow crystals; yield (1.7 g, 55%); mp 136–138°C; 1H-NMR spectrum (DMSO-d6) δ: 4.29 (2H, s), 7.18–8.26 (9H, m). IR (KBr) cm−1: 1602, 1346, 1180. MS m/z: 318 (M+), 237, 236, 235, 102, 78, 77. Anal. Calcd for C15H11ClN2O2S: C, 56.52; H, 3.48; Cl, 11.12; N, 8.79; S, 10.06. Found: C, 56.63; H, 3.43; Cl, 11.20; N, 8.93; S, 10.12. Synthesis of Ethyl 2-(4-Benzylphthalazin-1-ylthio)acetate (20) A solution of compound 16 (2.52 g, 0.01 mol), ethyl chloroacetate (4.4 g, 0.04 mol) and anhydrous potassium carbonate (5.5 g, 0.04 mol) in acetone (60 mL) was heated on water bath for 20 h. The excess solvent was evaporated and the reaction mixture was poured on water. The separated solid was filtered off and recrystallized from petroleum ether 60–80°C to give compound 20. Yellowish white crystals; yield (1.7 g, 54%); mp 74–76°C; 1H-NMR (DMSO-d6) δ: 1.19 (3H, t, J=6.0 Hz), 4.12–4.17 (2H, q, J=6.0 Hz), 4.30 (2H, s), 4.63 (2H, s), 7.15–8.28 (9H, m). IR (KBr) cm−1: 3061, 3030, 2978, 2923, 1737. MS m/z: 338 (M+), 294, 293, 266, 265, 252, 248, 203, 91 (100). Anal. Calcd for C19H18N2O2S: C, 67.43; H, 5.36; N, 8.28; S, 9.67. Found: C, 67.25; H, 5.53; N, 8.18; S, 9.60.


MATERIALS AND METHODS Biological Activities Antibacterial Activity Bacterial isolates were grown in nutrient broth medium (Oxoid) in an orbital shaking incubator for 24 h at 37°C. The bacterial growth centrifuged, washed twice with saline solution (0.9%) and then standardized to approximately 106 colony forming unit (CFU)/mL using nutrient broth medium, during the assay. Bacterial Sensitivity Test Standard well agar diffusion method was carried out to detect the activity of the compounds against the clinical bacterial isolates according to Cheesbrough38) Standard antibiotic discs (vancomycin, erythromycin and tetracycline) were placed uniformly on the surface of nutrient agar plates seeded with 100 µL of 24 h bacterial culture prepared as mentioned above. For antibacterial activities of the compounds wells were made in these plates then from each compound 100 µL (100 µg) was placed in each well. The plates were left in refrigerator for 2 h. After that were incubated at 37°C for 24 h. Diameter of inhibition zones around the wells were measured. All microbiological statistical analyses in this study were carried out using Microsoft Excel 2003 (Microsoft Corporation). All data were calculated from at least 2 replicates and the standard errors for each datum were plotted on the graph. Cytotoxicity Assay The cytotoxic activity of seven compounds was tested against four human tumor cell lines namely; hepatocellular carcinoma (liver) HePG-2, colon cancer HCT-116, human (prostate) cancer cell line PC3, and mammary gland (breast) MCF-7. The cell lines were obtained from ATC C via Holding Company for biological products and vaccines (VACSERA), Cairo, Egypt. 5-Fluorouracil was used as a standard anticancer drug for comparison. Chemical Reagents The reagents are RPMI-1640 medium, 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethylsulfoxide (DMSO) and 5-fluorouracil (Sigma Co., St. Louis, MO, U.S.A.), Fetal Bovine serum (GIBCO, U.K.). MTT Assay The different cell lines39,40) mentioned above was used to determine the inhibitory effects of compounds on cell growth using the MTT assay. This colorimetric assay is based on the conversion of the yellow MTT to a purple formazan derivative by mitochondrial succinate dehydrogenase in viable cells. The cells were cultured in RPMI-1640 medium with 10% fetal bovine serum. Antibiotics added were 100 units/mL penicillin and 100 µg/mL streptomycin at 37°C in a 5% CO2 incubator. The cells were seeded41) in a 96-well plate at a density of 1.0×104 cells/well at 37°C for 48 h under 5% CO2 incubator. After incubation the cells were treated with different concentration of compounds and incubated for 24 h. After 24 h of drug treatment, 20 µL of MTT solution at 5 mg/ mL was added and incubated for 4 h. DMSO in volume of 100 µL is added into each well to dissolve the purple formazan formed. The colorimetric assay is measured and recorded at absorbance of 570 nm using a plate reader (EXL 800 U.S.A.). The relative cell viability in percentage was calculated as (A570 of treated samples/A570 of untreated sample)×100. Antioxidant Assay ABTS Method For each of the investigated compounds42–44) (2 mL) of

ABTS solution (60 µM) was added to 3 mL MnO2 suspension (25 mg/mL), all prepared in (5 mL) aqueous phosphate buffer solution (pH 7, 0.1 M). The mixture was shaken, centrifuged, filtered and the absorbance of the resulting green blue solution (ABTS radical solution) at 734 nm was adjusted to approx. ca. 0.5. Then, 50 µL of (2 m M) solution of the tested compound in spectroscopic grade MeOH/phosphate buffer (1 : 1) was added. The absorbance was measured and the reduction in color intensity was expressed as inhibition percentage. L-Ascorbic acid was used as standard antioxidant (positive control). Blank sample was run without ABTS and using MeOH/phosphate buffer (1 : 1) instead of the tested compounds. Negative control was run with ABTS and MeOH/phosphate buffer (1 : 1) only. Bleomycin-Dependent DNA Damage Assay To the reaction mixtures45,46) in a final volume of 1.0 mL, the following reagents were added: DNA (0.2 mg/mL), bleomycin sulfate (0.05 mg/mL), FeCl3 (0.025 m M), magnesium chloride (5 m M), KH2PO4 –KOH buffer pH 7.0 (30 m M), and ascorbic acid (0.24 m M) or the test fractions diluted in MeOH to give a concentration of (0.1 mg/mL). The reaction mixtures were incubated in a water bath at 37°C for 1 h. At the end of the incubation period, 0.1 mL of ethylenediaminetetraacetic acid (EDTA) (0.1 M) was added to stop the reaction (the iron-EDTA complex is unreactive in the bleomycin assay). DNA damage was assessed by adding 1 mL 1% (w/v) thiobarbituric acid (TBA) and 1 mL of 25% (v/v) hydrochloric acid followed by heating in a water-bath maintained at 80°C for 15 min. The chromogen formed was extracted into 1-butanol, and the absorbance was measured at 532 nm. Acknowledgment Technical support from Department of Chemistry, Faculty of Science, Ain Shams University is gratefully acknowledged. Conflict of Interest interest.

The authors declare no conflict of

Supplementary Materials The online version of this article contains supplementary materials.

REFERENCES 1) Al’-Assar F, Zelenin KN, Lesiovskaya EE, Benzhan IP, Chakchir BA. Synthesis and pharmacological activity of 1-hydroxy-, 1-amino-, and 1-hydrazino-substituted 2,3-dihydro-1H-pyrazolo[1,2-a]pyridazine5,8-diones and 2,3-dihydro-1H-pyrazolo[1,2-b]phthalazine-5,10diones. Pharm. Chem. J., 36, 598–603 (2002). 2) Jain RP, Vederas JC. Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase. Bioorg. Med. Chem. Lett., 14, 3655–3658 (2004). 3) Carling RW, Moore KW, Street LJ, Wild D, Isted C, Leeson PD, Thomas S, O'Connor D, McKernan RM, Quirk K, Cook SM, Atack JR, Wafford KA, Thompson SA, Dawson GR, Ferris P, Castro JL. 3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. J. Med. Chem., 47, 1807–1822 (2004). 4) Demirayak S, Karaburun AC, Beis R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur. J. Med. Chem., 39, 1089–1095 (2004). 5) Munín J, Santana L, Uriarte Eu, Borges F, Quezada E. A compara-

250

6)

7)

8)

9)

10)

11)

12)

13)

14)

15)

16)

17)

18)

19)

20)

21)

Biol. Pharm. Bull. tive synthesis of 6-benzyl-2,3-dihydroimidazo[2,1-a]phthalazine and 2H-7-benzyl-3,4-dihydropyrimido[2,1-a]phthalazine. Tetrahedron Lett., 56, 828–830 (2015). Nomoto Y, Obase H, Takai TH, Teranishi M, Nakamura J, Kubo K. Studies on cardiotonic agents. II. Synthesis of novel phthalazine and 1,2,3-benzotriazine derivatives. Chem. Pharm. Bull., 38, 2179–2183 (1990). Grasso S, De Sarro G, De Sarro A, Micale N, Zappalà M, Puja G, Baraldi M, De Micheli C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones. J. Med. Chem., 43, 2851–2859 (2000). Sivakumar R, Kishore Guanasam S, Ramachandran S, Leonard JT. Pharmacological evaluation of some new 1-substituted-4-hydroxyphthalazines. Eur. J. Med. Chem., 37, 793–801 (2002). Madhavan GR, Chakrabarti R, Kumar SKB, Misra P, Mamidi RNVS, Balraju V, Kasiram K, Babu RK, Suresh J, Lohray BB, Lohrayb VB, Iqbal J, Rajagopalan R. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents. Eur. J. Med. Chem., 36, 627–637 (2001). Lenz EM, Wilson LD, Wright B, Partridge EA, Rodgers CT, Haycock PR, Lindon JC, Nicholson JK. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J. Pharm. Biomed. Anal., 28, 31–43 (2002). Johensen M, Rehse K, Pertz H, Stasch JP, Bischoff E. New antithrombotic 1-phthalazinamines with serotonin antagonistic properties. Arch. Pharm., 336, 591–597 (2003). Pramanik A. Synthesis of biologically important phthalazinones, 2,3-benzoxazin-1-ones and isoindolinones from ninhydrin and their antimicrobial activity. Tetrahedron Lett., 54, 3137–3143 (2013). Shetgiri NP, Nayak BK. Synthesis and antimicrobial activities of oxadiazoles, phthalazines and indolinones. Indian J. Chem., 44B, 1267–1272 (2005). Chakraborti AK, Gopalakrishnan B, Sobhia ME, Malde A. Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors. Bioorg. Med. Chem. Lett., 13, 2473–2479 (2003). Cockcroft X, Dillon KJ, Dixon L, Drzewiecki J, Kerrigan F, Loh VM Jr, Martin NMB, Menear KA, Smith GCM. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADPribose)polymerase. Bioorg. Med. Chem. Lett., 16, 1040–1044 (2006). Loh VM Jr, Cockcroft X, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews IT, Menear KA, Martin NM, Newton RF, Paul J, Smith GC, Vile J, Whittle AJ. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett., 15, 2235–2238 (2005). Eldehna WM, Ibrahim HS, Abdel-Aziz HA, Farrag NN, Youssef MM. Design, synthesis and in vitro antitumor activity of novel Nsubstituted-4-phenyl/benzylphthalazin-1-ones. Eur. J. Med. Chem., 89, 549–560 (2015). Haider N, Kabicher T, Käferböck J, Plenk A. Synthesis and in-vitro antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds. Molecules, 12, 1900–1909 (2007). Kim JS, Lee HJ, Suh ME, Choo HY, Lee SK, Park HJ, Kim C, Park SW, Lee CO. Synthesis and cytotoxicity of 1-substituted 2-methyl1H-imidazo[4,5-g]phthalazine-4,9-dione derivatives. Bioorg. Med. Chem., 12, 3683–3686 (2004). Demirayak S, Karaburun AC, Kayagil I, Erol K, Sirmagul B. Some pyridazinone and phthalazinone derivatives and their vasodilator activities. Arch. Pharm. Res., 27, 13–18 (2004). Duncton MAJ, Piatnitski EL, Katoch-Rouse R, Smith II LM 2nd, Kiselyov AS, Milligan DL, Balagtas C, Wong WC, Kawakami J, Doody JF. Arylphthalazines. Part 2: 1-(isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.

Vol. 39, No. 2 (2016)

Bioorg. Med. Chem. Lett., 16, 1579–1581 (2006). 22) Procopiou AP, Browning C, Buckley JM, Clark KL, Fechner L, Gore PM, Hancock AP, Hodgson ST, Holmes DS, Kranz M, Looker BE, Morriss KML, Parton DL, Russell LJ, Slack RJ, Sollis SL, Vile S, Watts CJ. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J. Med. Chem., 54, 2183–2195 (2011). 23) Hagiwara M, Endo T, Kanayama T, Hidaka H. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J. Pharmacol. Exp. Ther., 228, 467–471 (1984). 24) Vijay KS, Dinesh B, Jawahar LJ, Ganpat LT. Synthesis and antimicrobial activity of some 2-[1-(4-oxo-3,4-dihydrophthalazine-1-yl)alkyl]-1H-isoindole-1,3(2H)-dione and their imidoxy derivatives. ARKIVOC, xiv, 133–140 (2006). 25) Yamaguchi M, Kamei K, Koga T, Akima M, Kuroki T, Ohi N. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones. J. Med. Chem., 36, 4052–4060 (1993). 26) Papeo G, Casale E, Montagnoli A, Cirla A. PARP inhibitors in cancer therapy: an update. Expert Opin. Ther. Pat., 23, 503–514 (2013). 27) Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O’Connor MJ, Smith GC, Martin NM. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose)polymerase-1. J. Med. Chem., 51, 6581–6591 (2008). 28) Prime ME, Courtney SM, Brookfield FA, Marston RW, Walker V, Warne J, Boyd AE, Kairies NA, von der Saal W, Limberg A, Georges G, Engh RA, Goller B, Rueger P, Rueth M. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of aurora-A kinase. J. Med. Chem., 54, 312–319 (2011). 29) Kingston DG. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod., 72, 507–515 (2009). 30) Saeed BB, Al-Iraqi MA, Abachi FT. Synthesis of new 1,2-dithiol3-thione fluoroquinolone esters possessing anticancer activity invitro. Iraqi J. Vet. Sci, 26, 115–121 (2012). 31) El-Wahab AHFA, Mohamed HM, El-Agrody AM, El-Nassag MA, Bedair AH. Synthesis and biological screening of 4-benzyl-2Hphthalazine derivatives. Pharmaceuticals, 4, 1158–1170 (2011). 32) Barahman M, Pershang S. Michael addition of thiols to α,βunsaturated carbonyl compounds under solvent-free conditions. ARKIVOC, xii, 130–137 (2006). 33) Díaz I, Mohino F, Pérez-Pariente J, Sastre E. Study by TG–MS of the oxidation of SH-MCM-41 to SO3H-MCM. Thermochim. Acta, 413, 201–207 (2004). 34) Fromm E, Wittmann J. Derivate des p-nitrophenols. Ber. Deut. Chem. Ges., 41, 2264–2273 (1908). 35) Otzen T, Wempe EG, Kunz B, Bartels R, Lehwark-Yvetot G, Hänsel W, Schaper KJ, Seydel JK. Folate-synthesizing enzyme system as target for development of inhibitors and inhibitor combinations against Candida albicans—Synthesis and biological activity of new 2,4-diaminopyrimidines and 4′-substituted 4-aminodiphenyl sulfones. J. Med. Chem., 47, 240–253 (2004). 36) Pal M, Rao Veeramaneni V, Nagabelli M, Rao Kalleda S, Misra P, Rao Casturi S, Rao Yeleswarapu K. Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett., 13, 1639–1643 (2003). 37) Gutteridge JM, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of ‘free’ iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem. J., 199, 263–265 (1981). 38) Cheesbrough M. “District Laboratory Practice in Tropical Coun-

Biol. Pharm. Bull. Vol. 39, No. 2 (2016)251 tries,” Part 2. Cambridge University Press, Cambridge, UK, pp. 35–38, 62–69 (2000). 39) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55–63 (1983). 40) Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods, 89, 271–277 (1986). 41) Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba M, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394, 287–291 (1998). 42) Lissi EA, Modak B, Torres R, Escobar J, Urzua A. Total antioxidant potential of resinous exudates from Heliotropium species. A comparison of ABTS and DPPH methods. Free Radic. Res., 30, 471–477

(1999). 43) El-Gazzar ABA, Youssef MM, Youssef AMS, Abu-Hashem AA, Badria FA. Design and synthesis of azolopyrimidoquinolines, pyrimidoquinazolines as anti-oxidant, anti-inflammatory and analgesic activities. Eur. J. Med. Chem., 44, 609–624 (2009). 44) Aeschbach R, Löliger J, Scott BC, Murcia A, Butler J, Halliwell B, Aruoma OI. Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chem. Toxicol., 32, 31–36 (1994). 45) Abdel-Wahab BF, El-Ahl AA, Badria FA. Synthesis of new 2-naphthyl ethers and their protective activities against DNA damage induced by bleomycin–iron. Chem. Pharm. Bull., 57, 1348–1351 (2009). 46) Badria FA, Ameen M, Akl MR. Evaluation of cytotoxic compounds from Calligonum comosum L. growing in Egypt. Z. Naturforsch. C, 62, 656–660 (2007).